What is Flexion Therapeutics Inc known for?
FLEXION THERAPEUTICS, INC. Flexion Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the common form of arthritis.
Do analysts agree on Flexion Therapeutics (flex) stock's price target?
The company's average rating score is 2.22, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings. According to analysts' consensus price target of $12.43, Flexion Therapeutics has a forecasted upside of 36.3% from its current price of $9.12.
What is Flexion Therapeutics PE (flex) ratio?
The P/E ratio of Flexion Therapeutics is -4.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Is Flexion Therapeutics a buy right now?
What is the Chiffre d'affaires for Flexion Therapeutics?
Earnings Flash (FLXN) FLEXION THERAPEUTICS annonce un chiffre d'affaires de 28,2 millio.. Analyst Recommendations on FLEXION THERAPEUTICS, INC.
What happened flexion stock?
Flexion (ticker: FLXN) is being acquired by New Jersey-based Pacira BioSciences (PCRX) in a deal valued at around $427.5 million. Adamas (ADMS) is set to be acquired by Supernus Pharmaceuticals (SUPN) for approximately $400 million. Flexion and Pacira both specialize in developing non-opioid pain management solutions.
Is Flexion Therapeutics a good stock to buy?
Flexion Therapeutics has 17.00% upside potential, based on the analysts' average price target. Can I see which stocks the top-ranking analysts are rating? Yes, go to the Analysts' Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
Is FLXN a buy?
For example, a stock trading at $35 with earnings of $3 would have an earnings yield of 0.0857 or 8.57%....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Should I buy or sell Flexion Therapeutics stock right now?
7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 7 hold...
What is Flexion Therapeutics' stock price forecast for 2022?
7 brokerages have issued twelve-month target prices for Flexion Therapeutics' stock. Their forecasts range from $6.00 to $18.00. On average, they p...
How were Flexion Therapeutics' earnings last quarter?
Flexion Therapeutics, Inc. (NASDAQ:FLXN) released its quarterly earnings results on Wednesday, May, 12th. The specialty pharmaceutical company repo...
Who are Flexion Therapeutics' key executives?
Flexion Therapeutics' management team includes the following people: Michael D. Clayman , President, Chief Executive Officer & Director Fred Dris...
What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO?
46 employees have rated Flexion Therapeutics CEO Mike Clayman, MD on Glassdoor.com . Mike Clayman, MD has an approval rating of 85% among Flexion...
Who are some of Flexion Therapeutics' key competitors?
Some companies that are related to Flexion Therapeutics include ChemoCentryx (CCXI) , HUTCHMED (HCM) , Aurinia Pharmaceuticals (AUPH) , Arcus B...
What other stocks do shareholders of Flexion Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therape...
What is Flexion Therapeutics' stock symbol?
Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."
Who are Flexion Therapeutics' major shareholders?
Flexion Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading L...
Barchart Technical Opinion
Business Summary
The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.
